Evidence map›Paper›PMID 30197416›Full record

ArticleNutrition & diabetes2018

Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study.

Y E Lentferink, M P van der Aa, E G A H van Mill, C A J Knibbe, M M J van der Vorst

Open access · goldFull text read
In one paragraph

Article in Nutrition & diabetes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Serum Concentrations and Dietary Intake of Vitamin BInternational journal of molecular sciences · 2023
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Y E LentferinkDepartment of Pediatrics, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
M P van der AaDepartment of Pediatrics, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
E G A H van MillDepartment of Pediatrics, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
C A J KnibbeDepartment of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
M M J van der VorstDepartment of Pediatrics, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands. m.van.der.vorst@antoniusziekenhuis.nl.
St. Antonius Ziekenhuis · NLJeroen Bosch Ziekenhuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesOff-label metformin is nowadays frequently used for the treatment of obesity in adolescents. However, studies on long-term metformin treatment in adolescents with obesity are scarce. Therefore, an 18 month open label extension study following an 18 months randomized placebo-controlled trial (RCT) on the efficacy, safety, and tolerability of metformin in adolescents with obesity and insulin resistance was performed. SUBJECTS/

methodsAfter completion of the RCT, metformin was offered to all participants with a body mass index standard deviation score (BMI-sds) > 2.3 and Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) ≥ 3.4. Endpoints were change in BMI and HOMA-IR.

resultsOverall, 31/42 participants completed the extension study (74% girls, median age 14.8 (11.6 - 17.9), BMI 31.2 (22.3 - 45.1), HOMA-IR 3.4 (0.2 - 8.8)). At start, 22/42 (52.4%) participants were eligible for metformin of which 13 (59.0%) agreed with treatment. In participants who continued metformin, an increase was observed in BMI (+2.2 (+0.2 to +9.0)) and HOMA-IR (+13.7 (+1.6 to +48.3)). In metformin naive participants, BMI stabilized after an initial decrease (+0.5 (-2.1 to +5.1)). For HOMA-IR, a decrease was observed (-1.1 (-4.6 to +1.4)).

conclusionWhile metformin treatment in metformin naive participants seems to result in an initial decrease in BMI and HOMA-IR, there is no evidence for sustained effect after prolonged use in adolescents. Limited compliance and/or insufficient dose may explain the differences in long-term effects between adolescents and adults.

Indexed as

AdolescentBody Mass IndexChildFemaleHumansHypoglycemic AgentsInsulin ResistanceMaleMetforminOff-Label UsePediatric ObesityTreatment OutcomeHypoglycemic AgentsMetformin

Identifiers

PMID30197416
PMCPMC6129504
OpenAlexW2890922801

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.